# Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

> **NCT03432676** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- ATM Gene Mutation
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Homologous Recombination Deficiency
- Pancreatic Ductal Adenocarcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage IIA Pancreatic Cancer AJCC v8
- Stage IIB Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **DRUG:** Epacadostat
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03432676
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-31
- **Primary completion:** 2020-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Incyte (supporter of the study) is no longer going to support the study.
- **Last updated:** 2019-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03432676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03432676, "Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03432676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*